RSS Feed Print
Encouraging Results from Phase III Alzheimer's Studies
Myriam
Posted: Wednesday, September 19, 2012 5:46 PM
Joined: 12/6/2011
Posts: 3326


From Alzheimer's Daily News:


(Source: FierceBiotech) - GE Healthcare announced results from Phase III brain autopsy and biopsy studies on the investigational PET amyloid imaging agent, [18F]flutemetamol, which showed a strong concordance between [18F]flutemetamol images and Alzheimer's disease-associated beta amyloid brain pathology.


[18F]Flutemetamol is a PET imaging agent being developed by GE Healthcare for the detection of beta amyloid deposits in the brain.

 

The program examined a number of subjects including 180 end-of-life subjects and 49 subjects with suspected Normal Pressure Hydrocephalus, gait abnormalities and urinary incontinence. All participants received [18F]flutemetamol injection.

 

For patients from the four separate biopsy studies [18F]flutemetamol detected beta amyloid with a median sensitivity ranging from 75-100 percent and specificity ranging from 99-100 percent. A similar range was also found for autopsied subjects.

 

"We are encouraged that [18F]flutemetamol PET images accurately and consistently reflected beta amyloid levels in living patients," said Ville Leinonen of Kuopio University Hospital. "Currently, Alzheimer's disease is confirmed during autopsy studies, but if we can detect beta amyloid earlier, we can help physicians make a more timely clinical diagnosis that can impact disease management and treatment decisions."

 

Go to full story: http://www.equities.com